JP2005523329A5 - - Google Patents

Download PDF

Info

Publication number
JP2005523329A5
JP2005523329A5 JP2003587152A JP2003587152A JP2005523329A5 JP 2005523329 A5 JP2005523329 A5 JP 2005523329A5 JP 2003587152 A JP2003587152 A JP 2003587152A JP 2003587152 A JP2003587152 A JP 2003587152A JP 2005523329 A5 JP2005523329 A5 JP 2005523329A5
Authority
JP
Japan
Prior art keywords
glycyl
preparation according
aqueous preparation
alkali metal
aqueous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003587152A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005523329A (ja
JP3927954B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2003/004745 external-priority patent/WO2003086471A2/en
Publication of JP2005523329A publication Critical patent/JP2005523329A/ja
Publication of JP2005523329A5 publication Critical patent/JP2005523329A5/ja
Application granted granted Critical
Publication of JP3927954B2 publication Critical patent/JP3927954B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003587152A 2002-04-16 2003-04-15 カンプトテシン誘導体含有水性製剤およびそれを凍結乾燥した医薬組成物 Expired - Fee Related JP3927954B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002112864 2002-04-16
PCT/JP2003/004745 WO2003086471A2 (en) 2002-04-16 2003-04-15 Lyophilized and liquid preparations comprising a polysaccharide derivative of camptothecin

Publications (3)

Publication Number Publication Date
JP2005523329A JP2005523329A (ja) 2005-08-04
JP2005523329A5 true JP2005523329A5 (enExample) 2006-04-13
JP3927954B2 JP3927954B2 (ja) 2007-06-13

Family

ID=29243336

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003587152A Expired - Fee Related JP3927954B2 (ja) 2002-04-16 2003-04-15 カンプトテシン誘導体含有水性製剤およびそれを凍結乾燥した医薬組成物

Country Status (21)

Country Link
US (1) US20050215485A1 (enExample)
EP (1) EP1501549A2 (enExample)
JP (1) JP3927954B2 (enExample)
KR (1) KR100700963B1 (enExample)
CN (1) CN100544769C (enExample)
AR (1) AR039272A1 (enExample)
AU (1) AU2003223120B2 (enExample)
BR (1) BR0309283A (enExample)
CA (1) CA2480425A1 (enExample)
HR (1) HRP20040894A2 (enExample)
ME (1) MEP31308A (enExample)
MX (1) MXPA04010178A (enExample)
MY (1) MY136696A (enExample)
NO (1) NO20044964L (enExample)
PL (1) PL371677A1 (enExample)
RS (1) RS91204A (enExample)
RU (1) RU2315623C2 (enExample)
TW (1) TW200306314A (enExample)
UA (1) UA77295C2 (enExample)
WO (1) WO2003086471A2 (enExample)
ZA (1) ZA200408008B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2556254A1 (en) * 2004-02-13 2005-08-25 Kabushiki Kaisha Yakult Honsha Aqueous solution preparation containing camptothecins
CA2562904C (en) 2004-04-27 2013-07-02 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
US7767200B2 (en) 2005-07-14 2010-08-03 Wellstat Biologics Corporation Cancer treatment using viruses, fluoropyrimidines and camptothecins
JP2007260275A (ja) * 2006-03-29 2007-10-11 Transcutaneous Technologies Inc イオントフォレーシス装置及びイオントフォレーシス投与用組成物
BRPI1011753B8 (pt) 2009-06-22 2021-05-25 Wyeth Llc conjugados imunogênicos de polissacarídeo capsular de staphylococcus aureus de sorotipos 5 e 8, seu uso e composições que os compreendem
MX343111B (es) 2009-06-22 2016-10-25 Wyeth Llc Composiciones inmunogenicas de antigenos de staphylococcus aureus.
CN102764260B (zh) * 2011-04-30 2014-07-30 正大天晴药业集团股份有限公司 一种喜树碱衍生物的药物组合物及其制备方法
JP5983608B2 (ja) * 2011-07-15 2016-09-06 コニカミノルタ株式会社 溶解助剤を利用したリポソーム含有製剤およびその製造方法
JP6012902B1 (ja) 2014-12-26 2016-10-25 日本化薬株式会社 カンプトテシン類高分子誘導体の医薬製剤
EP3345654A4 (en) * 2015-09-03 2019-05-08 Nippon Kayaku Kabushiki Kaisha PHARMACEUTICAL COMPOSITION COMPRISING A CAMPTOTHECINPOLYMER DERIVATIVE
WO2017053920A1 (en) 2015-09-25 2017-03-30 Zy Therapeutics Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
RU2018129760A (ru) 2016-03-01 2020-04-01 Ниппон Каяку Кабусики Кайся Фармацевтический препарат, содержащий полимерное производное на основе камптотецина
CN109481691A (zh) * 2018-11-20 2019-03-19 珠海天香苑生物科技发展股份有限公司 吉西他滨-羧甲基多糖共轭物、制备方法及其用途
EP4438062A1 (en) * 2021-11-26 2024-10-02 Astellas Pharma Inc. Indocyanine compound-containing solid pharmaceutical composition

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340817A (en) * 1987-04-14 1994-08-23 Research Triangle Institute Method of treating tumors with anti-tumor effective camptothecin compounds
ATE136898T1 (de) * 1991-10-29 1996-05-15 Glaxo Wellcome Inc Wasserlösliche camptothecinderivate
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
IT1282673B1 (it) * 1996-02-23 1998-03-31 Ist Naz Stud Cura Dei Tumori Derivati della camptotecina e loro uso come agenti antitumorali
TW527183B (en) * 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
US6288072B1 (en) * 1999-12-29 2001-09-11 Monroe E. Wall Camptothecin β-alanine esters with topoisomerase I inhibition
AR030207A1 (es) * 2000-04-07 2003-08-13 Daiichi Seiyaku Co Composicion farmaceutica que contiene un derivado de camptotecina y procedimiento de preparacion de la misma
US6815435B2 (en) * 2000-07-13 2004-11-09 Daiichi Pharmaceutical Co., Ltd. Pharmaceutical compositions containing DDS compounds
TWI313609B (en) * 2001-08-21 2009-08-21 Mitsubishi Tanabe Pharma Corp Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor

Similar Documents

Publication Publication Date Title
JP5936546B2 (ja) 6−フルオロ−3−ヒドロキシ−2−ピラジンカルボキサミドのメグルミン塩
JP2005523329A5 (enExample)
US12053502B2 (en) Daptomycin formulations
ES2648367T3 (es) Procedimiento de preparación de una composición farmacéutica liofilizada que contiene mitomicina C
JPWO2012043700A1 (ja) 6−フルオロ−3−ヒドロキシ−2−ピラジンカルボキサミドのナトリウム塩
CA2341568A1 (en) Stabilized pharmaceutical composition in lyophilized form
PT1988913E (pt) Formulação líquida de g-csf
JPH1129497A5 (enExample)
KR100546450B1 (ko) 약학 조성물
JP7043156B2 (ja) ベンゾアゼピン化合物含有凍結乾燥組成物
JP2006137678A (ja) インターロイキン−2組成物
JP3927954B2 (ja) カンプトテシン誘導体含有水性製剤およびそれを凍結乾燥した医薬組成物
JPWO1999036065A1 (ja) 医薬組成物
JP4142149B2 (ja) バンコマイシンの凍結乾燥製剤
TWI242447B (en) An injectable pharmaceutical compositions of dalfopristine/quinupristine combination
AU740291B2 (en) Stabilized pharmaceutical compositions based on quinupristine and on dalfopristine and their preparation
WO2017085696A1 (en) Parenteral formulations of melphalan
JP2002201137A (ja) ビダラビン注射用乾燥製剤
JPH05967A (ja) 組織プラスミノーゲンアクチベーター含有製剤組成物
JPH01156925A (ja) ネオカルチノスタチン誘導体の凍結乾操製剤組成物
JPH0710753A (ja) 注射剤
JP2018095593A (ja) 凍結乾燥製剤及びその製造方法
HK1183014B (en) Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide
JPWO1998043643A1 (ja) アシクロビル水溶液製剤